SCHEMBL1637313

SCHEMBL1637313

CCCN(CCCCN(C)Cc1ccc(CN(Cc2ncc[nH]2)C(C)c2ncc[nH]2)cc1)CC(=O)O

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 4/20 0.55
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
ACHE P22303 5/20 0.34
BCHE P06276 4/20 0.34
TAAR1 Q96RJ0 3/20 0.34
PPARG P37231 1/20 0.33
PPARA Q07869 1/20 0.33
LTA4H P09960 1/20 0.33
CYP2D6 P10635 1/20 0.32
TSHR P16473 1/20 0.32
MAOB P27338 1/20 0.32
LMNA P02545 1/20 0.32
GLA P06280 1/20 0.32
BLM P54132 1/20 0.32
PMP22 Q01453 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1638357 0.94 CXCR4 (0.49) CXCR4TAAR1PPARGPPARACYP2D6
SCHEMBL1637975 0.92 CXCR4 (0.51) CXCR4TAAR1PPARGPPARACYP2D6
SCHEMBL1206163 0.92 CXCR4 (0.58) CXCR4MEN1KMT2AACHETAAR1
SCHEMBL1292672 0.86 CXCR4 (0.49) CXCR4BCHETAAR1CYP2D6TSHR
SCHEMBL1205956 0.86 CXCR4 (0.56) CXCR4TAAR1CYP2D6TSHRLMNA
SCHEMBL1638532 0.85 CXCR4 (0.47) CXCR4MEN1KMT2AACHETAAR1
SCHEMBL1636501 0.85 CXCR4 (0.47) CXCR4MEN1KMT2AACHETAAR1
SCHEMBL1206756 0.85 CXCR4 (0.47) CXCR4MEN1KMT2AACHETAAR1
SCHEMBL1638058 0.85 CXCR4 (0.48) CXCR4ACHETAAR1MAOB
SCHEMBL1637214 0.84 CXCR4 (0.48) CXCR4ACHEBCHETAAR1CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110172212-A1 AMINE-BASED COMPOUND AND USE THEREOF KUREHA CORPORATION (JP) 2011-07-14 US claimed
US-20070208007-A1 Amine-Based Compound and Use Thereof KUREHA CORPORATION (JP) 2007-09-06 US claimed
EP-1724263-A1 BASIC AMINE COMPOUND AND USE THEREOF Kureha Corporation (JP) 2006-11-22 EP claimed
US-20110172212-A1 AMINE-BASED COMPOUND AND USE THEREOF KUREHA CORPORATION (JP) 2011-07-14 US disclosed
US-7932281-B2 Amine-based compound and use thereof KUREHA CORPORATION (JP) 2011-04-26 US disclosed
US-20070208007-A1 Amine-Based Compound and Use Thereof KUREHA CORPORATION (JP) 2007-09-06 US disclosed
EP-1724263-A1 BASIC AMINE COMPOUND AND USE THEREOF Kureha Corporation (JP) 2006-11-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172212-A1 AMINE-BASED COMPOUND AND USE THEREOF NR0B2, NR5A2, NR1D2 CXCR4 86/4885MEN1 1008/4885KMT2A 474/4885
US-20070208007-A1 Amine-Based Compound and Use Thereof NR0B2, NR5A2, NR2E1 CXCR4 100/4885MEN1 1361/4885KMT2A 488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.